Physician profile
Brandy E Stewart
NPI 1801017116
$6,267.62
in general payments reported to CMS, 2019-2025
38 companies · $994 in 2025
The $994 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,526 · 2022: $1,414 · 2023: $1,468 · 2024: $865 · 2025: $994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,327.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,009.10 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $932.15 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $895.84 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $523.46 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $362.62 | 2021-2023 | Xifaxan |
| Abbott Laboratories | $217.98 | 2021-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $214.11 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.25 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $192.09 | 2021-2022 | |
| Glaxosmithkline, LLC. | $173.88 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $145.60 | 2021-2025 | Veozah |
| Sumitomo Pharma America, INC. | $139.59 | 2023-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $137.28 | 2023-2025 | Rexulti |
| Pfizer INC. | $106.94 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $93.82 | 2025 | Caplyta |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.